SCHEMBL3326236

SCHEMBL3326236

CC(C)(C)OC(=O)N1CC(c2ccc3c(cnn3S(=O)(=O)c3ccccc3)c2)C1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.44
RORC P51449 1/20 0.40
USP30 Q70CQ3 1/20 0.39
HPGDS O60760 2/20 0.39
HTR6 P50406 2/20 0.39
TGFBR1 P36897 1/20 0.39
TP53 P04637 3/20 0.38
MAPT P10636 1/20 0.38
NR1H2 P55055 2/20 0.38
NR1H3 Q13133 2/20 0.38
PIK3CA P42336 1/20 0.38
TNF P01375 1/20 0.38
LMNA P02545 1/20 0.38
PDE4B Q07343 1/20 0.38
SFRP1 Q8N474 2/20 0.37
PRMT5 O14744 1/20 0.37
BCHE P06276 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3327330 0.87 RORC (0.43) GPR119RORCUSP30HTR6TP53
SCHEMBL27774775 0.85 ALDH1A1 (0.41) GPR119HTR6MAPTPDE4B
SCHEMBL3327338 0.82 HTR6 (0.49) RORCHTR6LMNABCHE
SCHEMBL29849392 0.80 PDE1C (0.47) GPR119USP30PDE4B
SCHEMBL21385205 0.80 PDE1C (0.47) GPR119USP30PDE4B
SCHEMBL3328018 0.79 GPR119 (0.39) GPR119RORCUSP30
SCHEMBL23517419 0.79 TP53 (0.39) GPR119RORCHPGDSTP53NR1H2
Tert-Butyl Formate SCHEMBL27774776 0.77 HTR6 (0.37) RORCHTR6
SCHEMBL3327691 0.76 CYP2C19 (0.45) GPR119RORCHPGDSHTR6TGFBR1
SCHEMBL3330566 0.76 HTR6 (0.50) RORCHTR6TGFBR1NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507469-B2 Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor ABBOTT GMBH & CO. KG (DE) 2013-08-13 US disclosed
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-06-03 US disclosed
EP-2155724-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR Abbott GmbH & Co. KG (DE) 2010-02-24 EP disclosed
WO-2008116833-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR HTR6, HTR4, HTR3C GPR119 79/4885RORC 637/4885USP30 1782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.